RNAC — Cartesian Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
$9.30
+$0.02 (+0.22%)
Cartesian Therapeutics Inc. (RNAC) is a biotechnology company listed on NASDAQ. It is led by Carsten Brunn Ph.D., based in 7495 New Horizon Way, Frederick, MD, United States, 21703, with about 66 employees. Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Latest reported RNAC revenue for 2025-09-30 was $452.0K. Net income was -$35.9M. Revenue was up 51.7% from 2025-06-30 to 2025-09-30. RNAC currently screens at market cap $290.9M and trailing P/E 2.1.
Use this RNAC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RNAC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RNAC SEC filings page. Lician reads the product cache first so this HTML stays unique to Cartesian Therapeutics Inc. even when a live quote feed is slow.
About Cartesian Therapeutics Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Key Statistics
Market Cap
$290.95M
Volume
97,554
Previous Close
$10.06
Day Range
$10.05 – $10.88
P/E Ratio
2.10
EPS
-$4.49
Revenue
$38.91M
Net Income
-$77.42M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+49.6%
Profit Margin
-199.0%
Employees
66
RNAC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $38.91M | $26.00M | $110.78M | $85.08M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$77.42M | -$219.71M | $35.38M | -$25.69M |
| EPS (Diluted) | -$4.49 | -$49.76 | $0.10 | -$0.22 |
Total Assets
$435.02M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$212.61M
Operating Cash Flow
-$23.67M
Free Cash Flow
$0.00
Cartesian Therapeutics Inc. Company Information
- President, CEO & Director
- Carsten Brunn Ph.D.
- Headquarters
- 7495 New Horizon Way, Frederick, MD, United States, 21703
- Phone
- 301 348 8698
- IPO / Founded
- 2016-06-22
- Sector
- Healthcare
- Industry
- Biotechnology